...
首页> 外文期刊>Clinical and experimental nephrology >Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats
【24h】

Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats

机译:西尼地平和血管紧张素II受体阻滞剂在预防糖尿病自发性高血压大鼠糖尿病肾病中的作用

获取原文
获取原文并翻译 | 示例

摘要

Background: Cilnidipine (Cil) is an L/N-type calcium channel blocker (CCB) that is known to provide renal protection by decreasing the activity of the sympathetic nervous system and the renin-angiotensin system (RAS). However, very few studies have evaluated the renoprotective effects of Cil in hypertension complicated by diabetes mellitus. In this study, we compared the effects of cilnidipine and the L-type CCB, amlodipine (Aml), in combination with an angiotensin II receptor blocker (ARB) on diabetic nephropathy that developed as a result of inducing diabetes in hypertensive rats. Methods: Diabetes was induced in 9-week-old male spontaneously hypertensive rats by intraperitoneally injecting them with streptozotocin (40 mg/kg twice) and the rats (8 per group) were randomly assigned to receive valsartan (Val), Cil + Val, Aml + Val, or vehicle for 8 weeks through a gastric tube. Results: There were no significant differences in systolic blood pressure or plasma parameters between the two combination therapy groups. Blood pressure lowering by neither combination therapy significantly affected the glycemic variables. However, the increased glycogen levels in the kidney as a result of hyperglycemia were significantly suppressed in the groups that received combination therapy, and the increased proteinurea and glomerulosclerosis due to progression of the diabetic nephropathy were significantly suppressed in the Cil + Val group. In addition, a significant decrease in ED-1-positive cells was observed in the Cil + Val group alone. Conclusion: The results of this study suggested that the L/N-type CCB, cilnidipine, had additive antihypertensive and proteinuria-lowering effects when administered in combination with an ARB, even in type-1 diabetic rats, and that the L-type CCB, amlodipine, did not. Furthermore, combination therapy with cilnidipine and valsartan significantly reduced glycogen accumulation and ED-1-positive cell infiltration, suggesting that cilnidipine suppressed the excessive increase in the activity of the sympathetic nervous system and RAS through N-type calcium channel blockade. ? 2012 Japanese Society of Nephrology.
机译:背景:西尼地平(Cil)是一种L / N型钙通道阻滞剂(CCB),已知可通过降低交感神经系统和肾素-血管紧张素系统(RAS)的活性来提供肾脏保护。但是,很少有研究评估Cil对高血压并发糖尿病的肾脏保护作用。在这项研究中,我们比较了西尼地平和L型CCB氨氯地平(Aml)与血管紧张素II受体阻滞剂(ARB)联合治疗对糖尿病性肾病的影响,所述糖尿病性肾病是由于在高血压大鼠中诱发糖尿病而导致的。方法:对9周大的雄性自发性高血压大鼠进行腹膜内注射链脲佐菌素(40 mg / kg两次)诱发糖尿病,将大鼠(每组8只)随机分配接受缬沙坦(Val),Cil + Val, Aml + Val,或通过胃管溶媒8周。结果:两个联合治疗组之间的收缩压或血浆参数无显着差异。两种联合疗法均无法降低血压,从而显着影响血糖变量。但是,在接受联合治疗的组中,由于高血糖导致的肾脏糖原水平的增加被显着抑制,而在Cil + Val组中,由于糖尿病肾病的进展而导致的蛋白尿和肾小球硬化的增加被显着抑制。另外,仅在Cil + Val组中观察到ED-1阳性细胞的显着减少。结论:这项研究的结果表明,L / N型CCB西尼地平与ARB联合使用具有加性降压和蛋白尿降低的作用,即使在1型糖尿病大鼠中也是如此,L型CCB ,氨氯地平,没有。此外,西尼地平和缬沙坦的联合治疗显着降低了糖原积累和ED-1阳性细胞浸润,这表明西尼地平通过N型钙通道阻滞抑制了交感神经系统和RAS活性的过度增加。 ? 2012年日本肾脏病学会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号